TG Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2024. The company reported U.S. net product revenue for BRIUMVI of $103.6 million for Q4 2024, contributing to a full-year 2024 U.S. net product revenue of $310 million.
Total revenue for the fourth quarter of 2024 reached $108.2 million, and the company achieved a net income of $23.3 million, or $0.15 per diluted share, for the quarter. For the full year 2024, TG Therapeutics reported a profit of $23.4 million, or $0.15 per share, on total revenue of $329 million.
The company reaffirmed its target guidance of approximately $540 million in total global revenue for 2025. Additionally, TG Therapeutics highlighted the strengthening of its BRIUMVI patent portfolio through 2042, the launch of new clinical trials including for subcutaneous BRIUMVI, and overall pipeline advancement as key achievements for the year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.